SFM
KPRX icon

Spartan Fund Management’s Kiora Pharmaceuticals KPRX Stock Holding History

Spartan Fund Management’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-111
Closed -$6K – 417
2022
Q3 		$6K Buy
+111
New +$8.67K ﹤0.01% 353

Other funds holding KPRX

Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

Spartan Fund Management's KPRX Position: Q4 2022 in Review

Spartan Fund Management sold out of Kiora Pharmaceuticals (KPRX) in Q4 2022, closing a stake of 111 shares — an estimated $6K sold.

Spartan Fund Management first reported a position in KPRX in Q3 2022 and held it in 1 quarter. The position peaked at $6K in Q3 2022. 11 funds tracked by Wall St. Rank hold KPRX as of Q4 2022.

  • Spartan Fund Management reported no remaining Kiora Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Spartan Fund Management sold 111 Kiora Pharmaceuticals shares in Q4 2022, an estimated $6K.
  • Spartan Fund Management first reported a position in Kiora Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Spartan Fund Management's Kiora Pharmaceuticals position peaked at $6K in Q3 2022.
  • 11 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2022.

Based on Spartan Fund Management's 13F filing for Q4 2022, filed 24 Jan 2023.